YR1642
科研级 Sotrovimab (VIR-7831/GSK4182136), Anti-Spike Glycoprotein Recombinant Antibody, Research Grade Sotrovimab (VIR-7831/GSK4182136)
| Alias | 科研级 Sotrovimab (VIR-7831/GSK4182136), Anti-Spike Glycoprotein Recombinant Antibody, Research Grade Sotrovimab (VIR-7831/GSK4182136) |
| Catalog Number | YR1642 |
| Molecular Name | Sotrovimab (VIR-7831/GSK4182136) |
| Size | 1mg, 5mg |
| Clonity | Monoclonal |
| Purity | >95% as determined by SDS-PAGE |
| Concentration | 1mg/ml |
| Antibody Isotype | Human IgG |
| Formulation | PBS, pH7.5 |
| Background | Sotrovimab is an investigational monoclonal antibody therapy medication with activity against SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc. |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Remarks | This product is for research use only. |
| Shipping Condition | Shipped on ice packs. |
| Molecular Weight | 150 kDa |
| Target | Spike Glycoprotein[SARS-CoV-2] |
Service Account
0
